DPX-Survivac Triple Combo Holds Promise in Treating Advanced DLBCL, Phase 2 Trial Shows
News
IMV’s DPX-Survivac promotes anti-cancer responses and boosts the sensitivity of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to Keytruda (pembrolizumab) combined with chemotherapy, interim data from a Phase 2 study show. In the trial, ... Read more